Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, and health food/health supplements, as well as Chinese herbal active pharmaceutical ingredients and food addictives, and medical devices. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.
Research context
Sichuan Goldstone Asia Pharmaceutical Inc appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Industrials
- Industry
- Industrial Distribution
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Sichuan Goldstone Asia Pharmaceutical Inc is currently in a long term uptrend where the price is trading 2.9% above its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Industrials sector with a price to sales ratio of 3.7.
Sichuan Goldstone Asia Pharmaceutical Inc's total revenue sank by 22.6% to $147M since the same quarter in the previous year.
Its net income has dropped by 705.9% to $-99M since the same quarter in the previous year.
Finally, its free cash flow fell by 24.8% to $20M since the same quarter in the previous year.
Based on the above factors, Sichuan Goldstone Asia Pharmaceutical Inc gets an overall score of 2/5.